Skip to main content
Clinical Trials/NCT03177330
NCT03177330
Unknown
Not Applicable

Safety and Efficacy of Heparin Dosing Score Protocol for Anticoagulation During Polymyxin-B Hemoperfusion: a Retrospective Study

National Taiwan University Hospital1 site in 1 country30 target enrollmentMay 15, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Septic Shock
Sponsor
National Taiwan University Hospital
Enrollment
30
Locations
1
Primary Endpoint
premature cartridge clotting rate
Last Updated
8 years ago

Overview

Brief Summary

Polymyxin B hemoperfusion (PMX-HP) is mainly used to remove endotoxins in septic shock patients with intra-abdominal infections. Because of the concerns of postoperative bleeding, physicians may hesitate to use anticoagulation in patients with septic shock within a few hours after an abdominal operation. We developed a heparin dosing score protocol for heparin dosage adjustment. The purpose of the study is to examine the safety and efficacy of the heparin dosing score protocol.

Registry
clinicaltrials.gov
Start Date
May 15, 2017
End Date
July 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • intra-abdominal septic shock patients or documented Gram-negative bacterial septic shock patients who received polymyxin-B hemoperfusion in National Taiwan University Hospital during October 2013-December 2016

Exclusion Criteria

  • pregnant woman
  • patients with do-not-resuscitate declaration
  • uncontrolled bleeding within 24hr

Outcomes

Primary Outcomes

premature cartridge clotting rate

Time Frame: 2 hours

the incidence of premature cartridge clotting within 2hr

Secondary Outcomes

  • bleeding event rate(24 hours)

Study Sites (1)

Loading locations...

Similar Trials